Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general populationCOVID-19 백신 접종 및/또는 일반 인구의 감염 후 이종 SARS-CoV-2 체액 반응Article Published on 2022-05-212022-09-12 Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Adults age Anti-spike anti-Spike IgG assessment characterized correlated COVID-19 COVID-19 vaccination Critical decrease defined determinant Follow-up French Gender General population heterogeneity highlight humoral Infection intensity participant positively correlated profile protocol Reinfection SARS-CoV-2 SARS-COV-2 infection serological survey Serological testing subjects the antibody response the vaccine uninfected vaccination vaccine injection [DOI] 10.1038/s41598-022-11787-4 PMC 바로가기 [Article Type] Article
Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab리툭시맙으로 치료받은 다발성 경화증 환자에서 SARS-CoV-2 백신 접종에 대한 혈청학적 반응과 관련된 요인Article Published on 2022-05-022022-09-12 Journal: JAMA Network Open [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] accumulated age analyzed angiotensin-converting enzyme 2 Anti-RBD IgG anti-receptor-binding domain Anti-spike anti-Spike IgG antibodies antibody B cells B-cell binding antibody CD19+ CD4+ T-cell CD8+ T-cell cellular response cohort study conducted COVID-19 infection Cutoff cutoff value Diagnosis disease dose Factor first vaccination Follow-up greater identify IgG IgG antibodies Immunoglobulin interferon gamma median monoclonal antibody Multiple multiple sclerosis Neutralizing outcome outcomes Patient patients evaluated peptide pool positive response positive test result proportion prospective cohort study quantitation RBD reached response rituximab SARS-CoV-2 sclerosis serological response spot-forming unit T-cell Response the median Treatment university hospital vaccination vaccine response Vaccines were assessed were measured women [DOI] 10.1001/jamanetworkopen.2022.11497 PMC 바로가기 [Article Type] Article
Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases전신 염증성 질환이 있는 면역 저하 환자에서 알파 및 델타 변이체에 대한 BNT162b2 백신의 면역원성Article Published on 2022-05-012022-09-11 Journal: Annals of the rheumatic diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] abrogated Alpha alpha and delta variants analysed anti-spike antibodies anti-spike antibody anti-Spike IgG B-cell B.1.617.2 BNT162b2 BNT162b2 vaccine Breakthrough infection breakthrough infections Control controls COVID-19 Delta delta variant Delta variants dose effort Endpoint evaluate exhibiting healthcare humoral Humoral response Immune escape immunocompromised individual immunocompromised individuals Immunocompromised patient Immunocompromised patients immunogenicity impairing IMPROVE individual infected with SARS-CoV-2 Inflammatory diseases Kinetics methotrexate mounted neutralisation neutralising Neutralising activity of BNT162b2 Other Patient primary endpoints Prospective raise regimen responses rituximab SARS-CoV-2 secondary Secondary endpoints sera Seroconversion Specific T-cell response strain Strains Support systemic inflammatory disease systemic inflammatory diseases T-cell T-cell Response T-cell responses therapeutic treated vaccination Vaccine Viral viral fitness [DOI] 10.1136/annrheumdis-2021-221508 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trialHIV-1 감염 여부에 관계없이 살고 있는 사람들을 대상으로 한 SARS-CoV-2 재조합 스파이크 단백질 나노입자 백신의 면역원성과 안전성: 무작위, 대조, 2A/2B상 시험Clinical Trial Published on 2022-05-012022-09-12 Journal: The Lancet. HIV [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 1:1 amplification angiotensin-converting enzyme 2 anti-Spike IgG antibody Antiretroviral therapy article assigned baseline clinical Coalition Cohort COVID-19 COVID-19 vaccine death dosage Efficacy and safety ELISA endpoints enrolled enrolment evaluated first vaccination geometric mean titre GMT GMTs HIV-1 HIV-1 viral HIV-negative humoral immune response immunogenicity increased risk individual injection interim analysis intervention group Intramuscular injection less Local Matrix-M Melinda Gate multicentre neutralising antibody titres Novavax NVX-CoV2373 NVX-CoV2373 vaccine observer-blinded occurred PACTR202009726132275 participant Participants paucity of data Placebo placebo-controlled provided randomised Randomly reactive receive Recombinant spike protein Registered registry remained reported safety analysis SARS-CoV-2 SARS-CoV-2 nucleic acid SCR SCRs second vaccination Serious Adverse Event Serious Adverse Events seroconversion rate serostatus South Africa stratified study group Support systemic adverse event the placebo group the vaccine Trial vaccination Vaccine vaccine immunogenicity Volume was used were assessed [DOI] 10.1016/S2352-3018(22)00041-8 PMC 바로가기 [Article Type] Clinical Trial
Antibody response with SARS-CoV-2 inactivated vaccine (CoronaVac) in Turkish geriatric population터키 노인 인구에서 SARS-CoV-2 비활성화 백신(CoronaVac)에 대한 항체 반응Article Published on 2022-05-012022-09-11 Journal: Age and Ageing [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] affecting Anti-spike anti-Spike IgG Antibody Response association best Charlson Comorbidity Index clinical Comorbidity Comprehensive CoronaVac COVID-19 vaccine defined Factor frailty geriatric assessment group IgG antibodies IgG antibody Inactivated vaccine individual Infection influence knowledge neutralising neutralising antibody Older older people Patient patients performed Prevalence response duration SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike-specific SARS-CoV-2 spike-specific IgG antibodies scale second dose seronegative seropositive Seropositivity significantly higher Sinovac specific IgG antibodies the antibody response the vaccine three group three groups U/mL vaccination [DOI] 10.1093/ageing/afac088 PMC 바로가기 [Article Type] Article
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trialmRNA-1273 부스터 후 SARS-CoV-2에 대한 면역 반응: 공개 표지 2상 시험Clinical Trial Published on 2022-05-012022-09-11 Journal: Nature Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse reactions anti-Spike IgG antibody Antibody titer Antibody titers B.1.617.2 booster booster dose booster injection Booster vaccine Breakthrough infection caused Cell coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 criterion delta variant disease dose Effectiveness elicited ELISA evaluated exploratory follow-up period Frequency immunized immunogenicity individual Infection injection Local memory B memory B cell Meso Scale Discovery mRNA mRNA-1273 MSD NAb NAb titers neutralizing antibody non-inferiority non-randomized Open-label participant Phase 2 phase 2 trial Phase 3 primary immunogenicity raised reported respiratory Safe SARS-CoV-2 second dose Serious Adverse Event Serious Adverse Events severe acute respiratory syndrome Coronavirus significantly higher statistically systemic adverse reaction systemic adverse reactions titers vaccination Vaccine variants wild-type SARS-CoV-2 [DOI] 10.1038/s41591-022-01739-w PMC 바로가기 [Article Type] Clinical Trial
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccinesChAdOx1 또는 BNT162b2 백신 2회 접종 후 일반 인구에서 항체 반응 및 보호 상관 관계Article Published on 2022-05-012022-09-12 Journal: Nature Medicine [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome age anti-Spike IgG antibody Antibody Response BNT162b2 BNT162b2 vaccine booster dose ChAdOx1 clinically coronavirus COVID-19 Decline dose doses General population greater IgG level Immunity individual individuals Infection intervals investigated male natural infection recipient SARS-CoV-2 second dose second vaccination significantly increased trajectory United Kingdom vaccination Vaccine vaccine dose Vaccines [DOI] 10.1038/s41591-022-01721-6 PMC 바로가기 [Article Type] Article
A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days비활성화 백신의 세 번째 접종은 항 SARS-CoV-2 항체의 수준과 붕괴 시간을 극적으로 증가시켰지만 다시 실망스럽게 감소했습니다: 368일 동안 18개의 연속 시점에서 전향적, 종적, 코호트 연구Article Published on 2022-04-292022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% CI activate administration anti-RBD anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody Anti-spike anti-Spike IgG antibody antibody levels booster dose carried conversion rate CoronaVac COVID-19 Day decay dose Efficacy evaluate FIVE fold half-life half-live half-lives IgA IgA level IgG IgM immune immune characteristics immune protection Immunity inactivated Increased Level longitudinal management much lower neutralizing antibody over Point positive positive conversion Predictive predictive values Prospective prospective cohort study regimen regimens remained response revaccination SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variants second dose subset the SARS-CoV-2 time vaccination Vaccine volunteers [DOI] 10.3389/fimmu.2022.876037 PMC 바로가기 [Article Type] Article
Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers의료 종사자의 비활성화된 SARS-CoV-2 백신(CoronaVac) 2회 접종 후 체액성 면역 반응 평가Observational Study Published on 2022-04-012022-09-11 Journal: Public health [Category] COVID19(2023년), SARS, 임상, 진단, 치료기술, [키워드] Abbott absence age anti-Spike IgG antibody Assessing blood sample Blood samples CoronaVac COVID-19 pandemic cutoff value declined detection dose female first dose greater HCW HCWs healthcare worker Healthcare workers highest humoral immune response Humoral immunity Immunity immunoassay immunogenic immunogenicity Immunoglobulin Immunoglobulin G inactivated inactive Infection investigated Ireland male men Microparticle observational study performed positive prospective observational study receptor Receptor-binding domain reported risk S1 subunit SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 vaccine second dose second dose of vaccine Seropositivity significantly Spike protein susceptible the receptor-binding domain the S1 subunit the spike protein vaccination Vaccine virus was performed women [DOI] 10.1016/j.puhe.2022.01.011 PMC 바로가기 [Article Type] Observational Study
Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant in a nursing home 28 weeks after two doses of mRNA anti-COVID-19 vaccines: evidence of a waning immunitymRNA 항-COVID-19 백신 2회 접종 후 28주 만에 요양원에서 SARS-CoV-2 B.1.617.2(델타) 변종 발생: 면역 약화의 증거Article Published on 2022-04-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 48 hour 48 hours 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Anti-spike anti-Spike IgG Antibody Units B.1.617.2 B.1.617.2 SARS-CoV-2 variant binding antibody unit booster dose collected coronavirus coronavirus disease Coronavirus disease 2019 Coverage COVID-19 Delta diagnosed dose Effectiveness Evidence expressed Fisher exact test health worker health workers higher risk IgG Immunity index case Infection Italy Lineage material mRNA mRNA vaccine Neutralizing nursing home nursing home residents outbreak Quantitative Relative risk resident respiratory resulting risk RT-PCR SARS-CoV-2 SARS-COV-2 infection second dose Sequencing sera serum severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 severe disease titre vaccination Vaccine vaccine effectiveness variant waning immunity was determined was measured was performed WHO [DOI] 10.1016/j.cmi.2021.12.013 PMC 바로가기 [Article Type] Article